| Literature DB >> 35458586 |
Sabrin R M Ibrahim1,2, Alaa A Bagalagel3, Reem M Diri3, Ahmad O Noor3, Hussain T Bakhsh3, Gamal A Mohamed4.
Abstract
Pluchea indica (L.) Less. (Asteraceae) commonly known as Indian camphorweed, pluchea, or marsh fleabane has gained great importance in various traditional medicines for its nutritional and medicinal benefits. It is utilized to cure several illnesses such as lumbago, kidney stones, leucorrhea, inflammation, gangrenous and atonic ulcer, hemorrhoids, dysentery, eye diseases, itchy skin, acid stomach, dysuria, abdominal pain, scabies, fever, sore muscles, dysentery, diabetes, rheumatism, etc. The plant or its leaves in the form of tea are commonly used for treating diabetes and rheumatism. The plant is a rich source of calcium, vitamin C, dietary fiber, and β-carotene. Various biomolecules have been isolated from P. indica, including thiophenes, terpenes, quinic acids, sterols, lignans, phenolics, and flavonoids. The current review reports detailed information about the phytoconstituents and pharmacological relevance of P. indica and the link to its traditional uses. The reported studies validated the efficacy and safety of P. indica, as well as supported its traditional uses for treating various ailments and promoting health and well-being. Thus, this could encourage the development of this plant into a healthy food supplement or medicine for the prevention and treatment of various diseases. However, further studies on the drug interactions, mechanism of action, pharmacokinetics, toxicology, and metabolism, as well as clinical trials, should be carried out.Entities:
Keywords: Asteraceae; Pluchea indica; bioactivities; health and well-being; nutritional value; phytoconstituents; traditional uses
Mesh:
Substances:
Year: 2022 PMID: 35458586 PMCID: PMC9030395 DOI: 10.3390/molecules27082383
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Figure 1Structures of compounds 1–9.
List of reported metabolites from Pluchea indica.
| Compound Name | Plant Part | Extract/Fraction | Mol. Wt. | Mol. Formula | City, Country | Ref. |
|---|---|---|---|---|---|---|
| Monoterpenes | ||||||
| (+)-Linalool ( | Aerial parts | Polar fraction of MeOH extract | 154 | C10H18O | Drigh Road, Karachi, Pakistan | [ |
| Linaloyl glucopyranoside ( | Aerial parts | Polar fraction of MeOH extract | 316 | C16H28O6 | Drigh Road, Karachi, Pakistan | [ |
| Linaloyl apiosyl glucopyranoside ( | Aerial parts | Polar fraction of MeOH extract | 448 | C21H36O10 | Drigh Road, Karachi, Pakistan | [ |
| (+)-9-Hydroxylinalool ( | Aerial parts | Polar fraction of MeOH extract | 170 | C10H18O2 | Drigh Road, Karachi, Pakistan | [ |
| 9-Hydroxylinaloyl glucopyranoside ( | Aerial parts | Polar fraction of MeOH extract | 332 | C16H28O7 | Drigh Road, Karachi, Pakistan | [ |
| Plucheoside B ( | Aerial parts | Polar fraction of MeOH extract | 388 | C19H32O8 | Drigh Road, Karachi, Pakistan | [ |
| Thymol ( | Aerial parts | Polar fraction of MeOH extract | 150 | C10H14O | Drigh Road, Karachi, Pakistan | [ |
| Plucheoside C ( | Aerial parts | Polar fraction of MeOH extract | 444 | C21H32O10 | Drigh Road, Karachi, Pakistan | [ |
| (E)-4-(3-Hydroxybut-1-en-1-yl)-3,5,5-trimethylcyclohex-3-ene-1,2-diol ( | Aerial parts | Polar fraction of MeOH extract | 226 | C13H22O3 | Drigh Road, Karachi, Pakistan | [ |
| Sesquiterpenes | ||||||
| 3-(2′,3′-Diacetoxy-2′-methyl butyryl)-cuauhtemone ( | Leaves | CHCl3 fraction of EtOH extract | 452 | C24H36O8 | Nakornpathom, Thailand | [ |
| Cuauhtemone ( | Leaves | CHCl3 fraction of EtOH extract | 252 | C15H24O3 | Nakornpathom, Thailand | [ |
| Plucheoside A ( | Aerial parts | Polar fraction of MeOH extract | 412 | C21H32O8 | Drigh Road, Karachi, Pakistan | [ |
| Plucheoside E ( | Aerial parts | Polar fraction of MeOH extract | 400 | C21H36O7 | Drigh Road, Karachi, Pakistan | [ |
| Herbolide A ( | Aerial parts | Polar fraction of MeOH extract | 292 | C17H24O4 | Drigh Road, Karachi, Pakistan | [ |
| Pterocarptriol ( | Aerial parts | Polar fraction of MeOH extract | 256 | C15H28O3 | Drigh Road, Karachi, Pakistan | [ |
| Plucheol A ( | Aerial parts | Polar fraction of MeOH extract | 254 | C15H26O3 | Drigh Road, Karachi, Pakistan | [ |
| Plucheol B ( | Aerial parts | Polar fraction of MeOH extract | 254 | C15H26O3 | Drigh Road, Karachi, Pakistan | [ |
| (+)-Cyperone ( | Roots | CH2Cl2 fraction of MeOH extract | 218 | C15H22O | Kaohsiung, Taiwan | [ |
| Costunolide ( | Roots | CH2Cl2 fraction of MeOH extract | 232 | C15H20O2 | Kaohsiung, Taiwan | [ |
| Caryolane-1,9β-diol ( | Aerial parts | 238 | C15H26O2 | Hepu, Guangxi, China | [ | |
| (8R,9R)-Isocaryolane-8,9-diol ( | Aerial parts | 238 | C15H26O2 | Hepu, Guangxi, China | [ | |
| Clovane-2α,9β-diol ( | Aerial parts | 238 | C15H26O2 | Hepu, Guangxi, China | [ | |
| Valenc-1(10)-ene-8,11-diol ( | Aerial parts | 238 | C15H26O2 | Hepu, Guangxi, China | [ | |
| Valenc-1(10)-ene-8-hydroxy-11-O-glucopyranoside ( | Aerial parts | EtOAc fraction of MeOH extract | 400 | C21H37O7 | China | [ |
| (10S,11S)-Himachala-3-(12)-4-diene ( | Leaves | Essential oil | 204 | C15H24 | Sidoarjo and Surabaya, Indonesia | [ |
| Triterpenes | ||||||
| Taraxasterol ( | Leaves | 426 | C30H50O | Gia Lam, Hanoi, Vietnam | [ | |
| Taraxasterol acetate ( | Leaves | 468 | C32H52O2 | Gia Lam, Hanoi, Vietnam | [ | |
| Multiflorenol ( | Aerial parts | 426 | C30H50O | China | [ | |
| Sterols | ||||||
| Stigmasterol ( | Aerial parts | 412 | C29H48O | Hepu, Guangxi, China | [ | |
| Twigs | - | - | Vietnam | [ | ||
| Leaves | 412 | C29H48O | Gia Lam, Hanoi, Vietnam | [ | ||
| Stigmasterol 3-O-β-D-glucopyranoside ( | Aerial parts | Polar fraction of MeOH extract | 574 | C35H58O6 | Drigh Road, Karachi, Pakistan | [ |
| Twigs | EtOAc fraction of MeOH extract | - | - | Vietnam | [ | |
| Leaves | EtOAc fraction of MeOH extract | - | - | Gia Lam, Hanoi, Vietnam | [ | |
| β-Sitosterol ( | Twigs | 414 | C29H50O | Vietnam | [ | |
| β-Sitosterol 3-O-β-D-glucopyranoside ( | Leaves | EtOAc fraction of MeOH extract | 576 | C35H60O6 | Gia Lam, Hanoi, Vietnam | [ |
| Campesteryl ferulate ( | Leaves | EtOH extract | 576 | C38H56O4 | Hat Yai, Songkhla, Thailand | [ |
| Caffeoylquinic acid derivatives | ||||||
| 3-O-Caffeoylquinic acid ( | Aerial parts | Acidified MeOH | 354 | C16H18O9 | Seberang Perai, Malaysia | [ |
| Leaves | 50% EtOH extract | - | - | Different provinces in Thailand | [ | |
| 4-O-Caffeoylquinic acid ( | Leaves | 50% EtOH extract | 354 | C16H18O9 | Different provinces in Thailand | [ |
| 5-O-Caffeoylquinic acid ( | Aerial parts | Acidified MeOH | 354 | C16H18O9 | Seberang Perai, Malaysia | [ |
| Leaves | 50% EtOH extract | - | - | Different provinces in Thailand | [ | |
| 3,4-Di-O-Caffeoylquinic acid ( | Aerial parts | Acidified MeOH | - | - | Seberang Perai, Malaysia | [ |
| Leaves | 50% EtOH extract | 530 | C26H26O12 | Different provinces in Thailand | [ | |
| Leaves | 50% EtOH extract | - | - | Different provinces in Thailand | [ | |
| 3,5-Di-O-Caffeoylquinic acid ( | Aerial parts | Acidified MeOH | 516 | C25H24O12 | Seberang Perai, Malaysia | [ |
| Leaves | EtOAc fraction of MeOH extract | - | - | Yogyakarta, Indonesia | [ | |
| Leaves | 50% EtOH extract | - | - | Different provinces in Thailand | [ | |
| Leaves | 50% EtOH extract | - | - | Different provinces in Thailand | [ | |
| 4,5-Di-O-Caffeoylquinic acid ( | Aerial parts | Acidified MeOH | 516 | C25H24O12 | Seberang Perai, Malaysia | [ |
| 4,5-Di-O-caffeoylquinic acid methyl ester ( | Leaves | EtOAc fraction of MeOH extract | 530 | C26H26O12 | Yogyakarta, Indonesia | [ |
| Leaves | 50% EtOH extract | - | - | Different provinces in Thailand | [ | |
| 3,4,5-Tri-O-Caffeoylquinic acid ( | Leaves | EtOAc fraction of MeOH extract | 678 | C34H30O15 | Khon Kaen, Thailand | [ |
| Leaves | EtOAc fraction of MeOH extract | - | - | Yogyakarta, Indonesia | [ | |
| 3,4,5-Tri-O-Caffeoylquinic acid methyl ester ( | Leaves | EtOAc fraction of MeOH extract | 692 | C35H32O15 | Yogyakarta, Indonesia | [ |
| 1,3,4,5-Tetra-O-Caffeoylquinic acid ( | Leaves | EtOAc fraction of MeOH extract | 840 | C43H36O18 | Khon Kaen, Thailand | [ |
| Leaves | EtOAc fraction of MeOH extract | - | - | Yogyakarta, Indonesia | [ | |
| Flavonoids | ||||||
| Quercetin ( | Leaves | EtOAc fraction of MeOH extract | 302 | C15H10O7 | Khon Kaen, Thailand | [ |
| Aerial parts | Acidified 50% MeOH | - | - | Bogor, west Java, Indonesia | [ | |
| Aerial parts | EtOAc fraction of MeOH extract | - | - | Chantaburi, Thailand | [ | |
| Quercetin-3-O-β-D-glucopyranoside ( | Aerial parts | EtOAc fraction of MeOH extract | 464 | C21H20O12 | China | [ |
| Aerial parts | Acidified MeOH | - | - | Seberang Perai, Malaysia | [ | |
| Quercetin-3-O-β-D-galactopyranoside ( | Aerial parts | Acidified MeOH | 464 | C21H20O12 | Seberang Perai, Malaysia | [ |
| 3′,4′,5,7-Tetrahydroxy-flavone-3-O-β-D-mannopyranoside ( | Aerial parts | EtOAc fraction of MeOH extract | 464 | C21H20O12 | China | [ |
| Quercetin-3-O-sulphate ( | Aerial parts | Acidified MeOH | 382 | C15H10O10S | Seberang Perai, Malaysia | [ |
| Myricetin ( | Aerial parts | Acidified 50% MeOH | 318 | C15H10O8 | Bogor, west Java, Indonesia | [ |
| Kaempferol ( | Aerial parts | Acidified 50% MeOH | 286 | C15H10O6 | Bogor, west Java, Indonesia | [ |
| 6-Hydroxykaempferol 7-glucoside ( | 464 | C20H20O12 | Hat Yai, Songkhla, Thailand | [ | ||
| 4′,5,7-Trihydroxyflavone-3-O-β-D-glucoside ( | Aerial parts | EtOAc fraction of MeOH extract | 448 | C21H20O11 | China | [ |
| Apigenin ( | Aerial parts | Acidified 50% MeOH | 270 | C15H10O5 | Bogor, west Java, Indonesia | [ |
| Aerial parts | EtOAc fraction of MeOH extract | - | - | Chantaburi, Thailand | [ | |
| Apigenin 7-(2″,3″diacetylglucoside ( | [ | |||||
| Chrysoeriol ( | Aerial parts | EtOAc fraction of MeOH extract | 300 | C16H12O6 | Chantaburi, Thailand | [ |
| Luteolin ( | Aerial parts | Acidified 50% MeOH | 286 | C15H10O6 | Bogor, west Java, Indonesia | [ |
| Aerial parts | EtOAc fraction of MeOH extract | - | - | Chantaburi, Thailand | [ | |
| 8-Hydroxyluteolin 8-glucoside ( | Leaves | EtOH extract | 464 | C20H20O12 | Hat Yai, Songkhla, Thailand | [ |
| Phenolic acids, aldehydes, esters, and ketones | ||||||
| P-Hydroxybenzoic acid ( | Aerial parts | CHCl3 fraction of EtOH extract | 138 | C7H6O3 | Hepu, Guangxi, China | [ |
| 3,4,5-Trimethoxybenzoic acid ( | Roots | CH2Cl2 fraction of MeOH extract | 212 | C10H12O5 | Kaohsiung, Taiwan | [ |
| Caffeic acid ( | Aerial parts | EtOAc fraction of MeOH extract | 180 | C9H8O4 | China | [ |
| P-Hydroxybenzaldehyde ( | Roots | CH2Cl2 fraction of MeOH extract | 122 | C7H6O2 | Kaohsiung, Taiwan | [ |
| 3,4-Dihydroxy benzaldehyde ( | Aerial parts | CHCl3 fraction of EtOH extract | 138 | C7H6O3 | Hepu, Guangxi, China | [ |
| Vanillin ( | Aerial parts | CHCl3 fraction of EtOH extract | 152 | C8H8O3 | Hepu, Guangxi, China | [ |
| 3,4-Dihydroxy-5-methoxybenzaldehyde ( | Aerial parts | EtOAc fraction of MeOH extract | 168 | C8H8O4 | China | [ |
| Aerial parts | CHCl3 fraction of EtOH extract | - | - | Hepu, Guangxi, China | [ | |
| Syringicaldehyde ( | Aerial parts | CHCl3 fraction of EtOH extract | 182 | C9H10O4 | Hepu, Guangxi, China | [ |
| Trans-Coniferyl aldehyde ( | Aerial parts | CHCl3 fraction of EtOH extract | 178 | C10H10O3 | Hepu, Guangxi, China | [ |
| Dibutylphthalate ( | Aerial parts | CHCl3 fraction of EtOH extract | 278 | C16H22O4 | Hepu, Guangxi, China | [ |
| Ethyl caffeate ( | Aerial parts | CHCl3 fraction of EtOH extract | 208 | C11H12O4 | Hepu, Guangxi, China | [ |
| 2,3-Dihydroxy-1-(4-hydroxy-3-methoxyphenyl)-propan-1-one ( | Aerial parts | CHCl3 fraction of EtOH extract | 212 | C10H12O5 | Hepu, Guangxi, China | [ |
| Phenolics and phenolic glucosides | ||||||
| 1,2-Bis-(4-Hydroxy-3-methoxyphenyl)-propane-1,3-diol (erythro) ( | Aerial parts | Polar fraction of MeOH extract | 320 | C17H20O6 | Drigh Road, Karachi, Pakistan | [ |
| 1,2-Bis-(4-Hydroxy-3-methoxyphenyl)-propane-1,3-diol (threo) ( | Aerial parts | Polar fraction of MeOH extract | 320 | C17H20O6 | Drigh Road, Karachi, Pakistan | [ |
| 1-(4-Hydroxy-3-methoxyphenyl)-2-{4-[(1E)-3-hydroxyprop-1-en-1-yl]-2-methoxyphenoxy}-propane-1,3-diol (erythro) ( | Aerial parts | Polar fraction of MeOH extract | 360 | C20H24O6 | Drigh Road, Karachi, Pakistan | [ |
| 1-(4-Hydroxy-3-methoxyphenyl)-2-{4-[(1E)-3-hydroxyprop-1-en-1-yl]-2-methoxyphenoxy}-propane-1,3-diol (threo) ( | Aerial parts | Polar fraction of MeOH extract | 360 | C20H24O6 | Drigh Road, Karachi, Pakistan | [ |
| Esculetin ( | Aerial parts | CHCl3 fraction of EtOH extract | 178 | C9H6O4 | Hepu, Guangxi, China | [ |
| 3,4,5-Trimethoxyphenyl-β-D-glucopyranoside ( | Roots | CH2Cl2 fraction of MeOH extract | 346 | C15H22O9 | Kaohsiung, Taiwan | [ |
| Benzyl glucopyranoside ( | Aerial parts | Polar fraction of MeOH extract | 270 | C13H18O6 | Drigh Road, Karachi, Pakistan | [ |
| Phenylethyl glucopyranoside ( | Aerial parts | Polar fraction of MeOH extract | 284 | C14H20O6 | Drigh Road, Karachi, Pakistan | [ |
| Methyl salicylate glucoside ( | Aerial parts | Polar fraction of MeOH extract | 314 | C14H18O8 | Drigh Road, Karachi, Pakistan | [ |
| 4-Allyl-2-methoxy-6-hydroxyphenylglucoside ( | Aerial parts | EtOAc fraction of MeOH extract | 342 | C16H22O8 | China | [ |
| 4-Allyl-2,6-dimethoxy phenyl glucopyranoside ( | Aerial parts | Polar fraction of MeOH extract | 356 | C17H24O8 | Drigh Road, Karachi, Pakistan | [ |
| Eugenyl glucoside (Citrucin C) ( | Aerial parts | Polar fraction of MeOH extract | 326 | C16H22O7 | Drigh Road, Karachi, Pakistan | [ |
| Tangshenoside Ⅱ ( | Aerial parts | EtOAc fraction of MeOH extract | 372 | C17H24O9 | China | [ |
| Thalictoside ( | Roots | CH2Cl2 fraction of MeOH extract | 329 | C14H19NO8 | Kaohsiung, Taiwan | [ |
| Lignans and their derivatives | ||||||
| (+)-Syringaresinol ( | Roots | CH2Cl2 fraction of MeOH extract | 418 | C22H26O8 | Kaohsiung, Taiwan | [ |
| (+)-Diasyringaresinol ( | Roots | CH2Cl2 fraction of MeOH extract | 418 | C22H26O8 | Kaohsiung, Taiwan | [ |
| Aerial parts | CHCl3fraction of EtOH extract | - | - | Hepu, Guangxi, China | [ | |
| (+)-Epi-Syringaresinol ( | Roots | CH2Cl2 fraction of MeOH extract | 418 | C22H26O8 | Kaohsiung, Taiwan | [ |
| Syringaresinol monoglucopyranoside ( | Aerial parts | Polar fraction of MeOH extract | 580 | C28H36O13 | Drigh Road, Karachi, Pakistan | [ |
| Pinoresinol ( | Aerial parts | EtOAc fraction of MeOH extract | 358 | C20H22O6 | China | [ |
| (+)-Epi-Pinoresinol ( | Aerial parts | EtOAc fraction of MeOH extract | 358 | C20H22O6 | China | [ |
| Pinoresinol monoglucopyranoside ( | Aerial parts | Polar fraction of MeOH extract | 520 | C26H32O11 | Drigh Road, Karachi, Pakistan | [ |
| Liriodendrin ( | Roots | CH2Cl2 fraction of MeOH extract | 742 | C34H46O18 | Kaohsiung, Taiwan | [ |
| Plucheoside D1 ( | Aerial parts | Polar fraction of MeOH extract | 518 | C26H30O11 | Drigh Road, Karachi, Pakistan | [ |
| Plucheoside D2 ( | Aerial parts | Polar fraction of MeOH extract | 548 | C27H32O12 | Drigh Road, Karachi, Pakistan | [ |
| Plucheoside D3 ( | Aerial parts | Polar fraction of MeOH extract | 534 | C27H34O11 | Drigh Road, Karachi, Pakistan | [ |
| Hedyotisol A ( | Aerial parts | Polar fraction of MeOH extract | 810 | C42H50O16 | Drigh Road, Karachi, Pakistan | [ |
| Hedyotisol B ( | Aerial parts | Polar fraction of MeOH extract | 810 | C42H50O16 | Drigh Road, Karachi, Pakistan | [ |
| Trans-Trismethoxy resveratrol-d4 ( | Leaves | EtOH extract | 274 | C17H14D4O3 | Hat Yai, Songkhla, Thailand | [ |
| Threo-2,3-Bis(4-hydroxy-3-methoxyphenyl)-3-ethoxypropan-1-ol ( | Aerial parts | EtOAc fraction of EtOH extract | 348 | C19H24O6 | Hepu, Guangxi, China | [ |
| Erythro-2,3-Bis(4-hydroxy-3-methoxyphenyl)-3-ethoxypropan-1-ol ( | Aerial parts | EtOAc fraction of EtOH extract | 348 | C19H24O6 | Hepu, Guangxi, China | [ |
| (+)-Isolariciresinol ( | Aerial parts | EtOAc fraction of EtOH extract | 360 | C20H24O6 | Hepu, Guangxi, China | [ |
| (+)-9′-Isovaleryllariciresinol ( | Aerial parts | EtOAc fraction of EtOH extract | 444 | C25H32O7 | Hepu, Guangxi, China | [ |
| Thiophenes and their derivatives | ||||||
| 2-(Pro-1-ynyl)-5-(5,6-dihydroxypenta-1,3-diynyl) thiophene (PYDDT) = 2-(Prop-1-ynyl)-5(5,6-dihydroxyhexa-1, 3-diynyl)-thiophene = PITC-2 = R/J/3 ( | Roots | EtOAc fraction of MeOH extract | 230 | C13H10O2S | West Bengal, India | [ |
| Aerial parts | - | - | Chantaburi, Thailand | [ | ||
| Leaves | - | - | Gia Lam, Hanoi, Vietnam | [ | ||
| Roots | EtOAc fraction of MeOH extract | - | - | West Bengal, India | [ | |
| Twigs | - | - | Vietnam | [ | ||
| 2-(4-Hydroxy-3-methoxybut-1-yn-1-yl)-5-(penta-1,3-diyn-1-yl)thiophene ( | Aerial parts | EtOAc fraction of MeOH extract | 244 | C14H12O2S | Guangzhou, China | [ |
| 2-(3,4-Dihydroxybut-1-yn-1-yl)-5-(penta-1,3-diyn1-yl)thiophene ( | Aerial parts | EtOAc fraction of MeOH extract | 230 | C13H10O2S | Guangzhou, China | [ |
| 2-(3-Acetoxy-4-hydroxybut-1-yn-1-yl)-5-(penta-1,3-diyn-1-y1) thiophene ( | Aerial parts | EtOAc fraction of MeOH extract | 272 | C15H12O3S | Guangzhou, China | [ |
| 2-(Prop-1-yn-1-yl)-5-(6-acetoxy-5-hydroxyhexa-1,3-diyn-1-yl) thiophene = 2-(Prop-1-inyl)-5-(6-acetoxy-5-hydroxyhexa-1,3-diinyl) thiophene ( | Aerial parts | EtOAc fraction of MeOH extract | 272 | C15H12O3S | Guangzhou, China | [ |
| Aerial parts | - | - | Chantaburi, Thailand | [ | ||
| 2-(Penta-1,3-diyn-1-yl)-5-(4-acetoxy-3-hydroxybuta-1-yn-1-yl) thiophene ( | Aerial parts | 272 | C15H12O3S | Chantaburi, Thailand | [ | |
| 3″R-Pluthiophenol ( | Aerial parts | 230 | C13H10O2S | Hepu, Guangxi, China | [ | |
| 3″R-Pluthiophenol-4″-acetate ( | Aerial parts | 272 | C15H12O3S | Hepu, Guangxi, China | [ | |
| 3″-Ethoxy-3″S-pluthiophenol ( | Aerial parts | 258 | C15H14O2S | Hepu, Guangxi, China | [ | |
| 3″-Ethoxy-3″S-pluthiophenol-4″-acetate ( | Aerial parts | 300 | C17H16O3S | Hepu, Guangxi, China | [ | |
| 2-(4-O-β-Glucopyranosyl-3-hydroxybut-1-yn-1-yl)-5-(penta-1,3-diyn-1-yl)thiophene ( | Aerial parts | EtOAc fraction of MeOH extract | 392 | C19H20O7S | Guangzhou, China | [ |
| Other metabolites | ||||||
| 1-Dotriacontanol ( | Leaves | 466 | C32H66O | Gia Lam, Hanoi, Vietnam | [ | |
| 9,12,13-Trihydroxyoctadeca-10(E),15(Z)-dienoic acid ( | Aerial parts | 328 | C18H32O5 | Hepu, Guangxi, China | [ | |
| Pinellic acid ( | Aerial parts | 330 | C18H34O5 | Hepu, Guangxi, China | [ | |
| 1-Eicosanoyl glycerol ( | Twigs | 386 | C23H46O4 | Vietnam | [ | |
| Methyl 9-hydroxynonanoate ( | Aerial parts | 188 | C10H20O3 | Hepu, Guangxi, China | [ | |
| Triethyl citrate ( | Aerial parts | 276 | C12H20O7 | Hepu, Guangxi, China | [ | |
| (Z)-3-Hexenyl glucopyranoside ( | Aerial parts | Polar fraction of MeOH extract | 262 | C12H22O6 | Drigh Road, Karachi, Pakistan | [ |
| Fraxinellone ( | Aerial parts | 232 | C14H16O3 | Hepu, Guangxi, China | [ | |
| Adenosine ( | Aerial parts | EtOAc fraction of EtOH extract | 267 | C10H13N5O4 | Hepu, Guangxi, China | [ |
| Uridine 5′-monophosphate ( | Aerial parts | EtOAc fraction of MeOH extract | 324 | C9H13N2O9P | China | [ |
Biological activities results of extracts and/or faction of P. indica.
|
|
|
|
|
| |
|
|
| ||||
| Root/MeOH fraction of the defatted chloroform extract | Anti-inflammatory | Carrageenin-induced paw edema/Charles Foster rats | 0.103 mL (Paw volume, 100 mg/kg) | Phenylbutazone 0.204 mL (Paw volume) | [ |
| 0.046 mL (Paw volume, 300 mg/kg) | |||||
| 75.2 (%Inhibition, 100 mg/kg) | Phenylbutazone 50.9 (%Inhibition) | [ | |||
| 88.9 (%Inhibition, 300 mg/kg) | |||||
| Carrageenin-induced paw edema/adrenalectomized rats | 0.113 mL (Paw volume, 300 mg/kg) | Phenylbutazone 0.31 mL (Paw volume) | [ | ||
| 80.7 (%Inhibition, 300 mg/kg) | Phenylbutazone 45.4 (%Inhibition) | [ | |||
| Mediator-induced edema/Histamine | 0.030 mL (Paw volume, 300 mg/kg) | Control* 0.313 mL (Paw volume) | [ | ||
| Mediator-induced edema/Histamine | 0.180 mL (Paw volume, 300 mg/kg) | Control* 0.403 mL (Paw volume) | [ | ||
| Mediator-induced edema/Histamine | 0.030 mL (Paw volume, 300 mg/kg) | Control* 0.353 mL (Paw volume) | [ | ||
| Carrageenin-induced | 46.9 mg (Rear paw weight, 100 mg/kg) | Phenylbutazone 24.7 mg (Rear paw weight) | [ | ||
| 27.4 mg (Rear paw weight, 300 mg/kg) | [ | ||||
| Cotton pellet-induced granuloma/Charles Foster rats | 26.2 g (Granuloma weight, 100 mg/kg) | Phenylbutazone 15.4 g (Granuloma weight) | [ | ||
| 21.8 g (Granuloma weight, 300 mg/kg) | [ | ||||
| 41.9 (%Inhibition, 100 mg/kg) | Phenylbutazone 65.7 (%Inhibition) | [ | |||
| 51.8 (%Inhibition, 300 mg/kg) | [ | ||||
| Carrageenin-induced granuloma/Charles Foster rats | 1.22 g (Granuloma weight, 100 mg/kg) | Phenylbutazone 2.65 g (Granuloma weight) | [ | ||
| 1.00 g (Granuloma weight, 300 mg/kg) | [ | ||||
| 63.1 (%Inhibition, 100 mg/kg) | Phenylbutazone 19.9 (%Inhibition) | [ | |||
| 69.8 (%Inhibition, 100 mg/kg) | [ | ||||
| Sodium urate-inducededema/Charles Foster rats | 0.40 (Rear paw weight, 100 mg/kg) | Control* 0.68 (Rear paw weight) | [ | ||
| 0.22 (Rear paw weight, 300 mg/kg) | [ | ||||
| Root/MeOH extract | Antiulcer | Indomethacin-induced gastric ulcer/Charles Foster rats | 2.50 mm (Ulcer lesion index, 100 mg/kg) | Control* 4.7 1 (Ulcer lesion index) | [ |
| 0.83 (Ulcer lesion index, 300 mg/kg) | [ | ||||
| 46.92 (%Inhibition, 100 mg/kg) | [ | ||||
| 82.37 (%Inhibition, 300 mg/kg) | |||||
| Alcohol-induced gastric ulcer/Charles Foster rats | 1.33 (Ulcer lesion index, 100 mg/kg) | Control* 4.1 (Ulcer lesion index) | [ | ||
| 1.16 (Ulcer lesion index, 300 mg/kg) | [ | ||||
| 67.56 (%Inhibition, 100 mg/kg) | [ | ||||
| 71.70 (%Inhibition, 300 mg/kg) | [ | ||||
| Alcohol-indomethacin-induced gastric ulcer/Charles Foster rats | 5.72 (Ulcer lesion index, 100 mg/kg) | Control* 19.73 (Ulcer lesion index) | [ | ||
| 4.36 (Ulcer lesion index, 300 mg/kg) | [ | ||||
| 71.0 (%Inhibition, 100 mg/kg) | [ | ||||
| 78.0 (%Inhibition, 300 mg/kg) | [ | ||||
| Gastric secretion following pyloric ligation/Charles Foster rats | 13.0 mEq acid (HCl)/1/h (Total acidity, 100 mg/kg) | *Control 16.25 mEq acid (HCl)/1/h | [ | ||
| 7.5 mEq acid (HCl)/1/h (Total acidity, 300 mg/kg) | [ | ||||
| 9.00 mEq acid (HCl)/1/h (Total acidity, 100 mg/kg) | *Control 9.5 mEq acid (HCl)/1/h | [ | |||
| 5.16 mEq acid (HCl)/1/h (Total acidity, 300 mg/kg) | [ | ||||
| 10.3 mg Tyrosin/mL (Peptic activity, 100 mg/kg) | Control* 11.03 Tyrosin/mL (Peptic activity) | [ | |||
| 9.6 Tyrosin/mL (Peptic activity, 300 mg/kg) | [ | ||||
| PAF-induced gastric ulcer/Charles Foster rats | 15.0 mm (Ulcer lesion index, 100 mg/kg) | BW 755C 8.33 mm (Ulcer lesion index) | [ | ||
| 11.66 mm (Ulcer lesion index, 300 mg/kg) | BW 755C 8.33 mm (Ulcer lesion index) | [ | |||
| 35.6 (%Inhibition, 100 mg/kg) | BW 755C 64.2 (%Inhibition) | [ | |||
| 50.2 (%Inhibition, 300 mg/kg) | BW 755C 64.2 (%Inhibition) | [ | |||
| PAF-induced hematological change/Charles Foster rats | 41.2 (Haematocrit % change, 300 mg/kg) | BW 755C 37.6 (Haematocrit% change) | [ | ||
| 20.4 (RBC % change) | BW 755C 14.3 (RBC % change) | [ | |||
| 25.2 (Hemoglobin % change) | BW 755C 21.2 (Hemoglobin | [ | |||
| 15.8 (WBC % change) | BW 755C 16.6 (WBC % change) | [ | |||
| Croton oil-induced ear edema/Swiss A mice | 3.3 mg (Weight of 5 mm ear-punch, 100 mg/kg) | *Control 19.6 mg (Weight of 5 mm ear-punch | [ | ||
| 6.8 mg (Weight of 5 mm ear-punch, 300 mg/kg) | - | [ | |||
| 7.2 mg (Weight of 5 mm ear-punch, 250 µg/ear) | - | [ | |||
| 15.4 mg (Weight of 5 mm ear-punch, 500 µg/ear) | - | [ | |||
| Root/EtOH extract | Antioxidant | Hydroxyl (OH) radical-scavenging | 10.77 µg/mL (OH radicals IC50) | Vitamin E 33.2 µg/mL (OH radicals, IC50) | [ |
| CCl4-induced lipid peroxidation/Swiss albino mice | 54.5 (%Inhibition, 300 µg/mL) | vitamin E 46.28 (%Inhibition) | [ | ||
| Hydrogen peroxide (H2O2)-scavenging/Charles Foster rats | 65.2 (% Lysis of erythrocytes, 10 µg/mL) | BW 755C 86.9 (% Lysis of erythrocytes) | [ | ||
| Root/EtOH extract | Cytotoxic | NPC-TW 01 cells/WST-1 colorimetric assay | 14.07 (%Migration, 80 µg/mL) | - | [ |
| 5.65 (%Relative migration rate, 80 µg/mL) | - | [ | |||
| 24.57 (%Colony forming efficiency, 50 µg/mL) | - | [ | |||
| 108.5 µg/mL (24 h) (Growth inhibition 50%) | - | [ | |||
| NPC-TW04/WST-1 colorimetric assay | 7.76 (%Migration, 60 µg/mL) | - | [ | ||
| 93.2 (24 h) (Growth inhibition 50%) | - | [ | |||
| 3.47 (%Relative migration rate, 60 µg/mL) | - | [ | |||
| Leaves/EtOAc fraction | Anti-inflammatory | EPP-induced ear edema/Male Sprague Dawley rats | 8.30 µm (15 min) (ED, 3 mg/ear) | PB 3.3 µm (15 min) | [ |
| 18.30 µm (30 min) (ED, 3 mg/ear) | PB 25.0 µm (30 min) | ||||
| 45 µm (60 min) (ED, 3 mg/ear) | PB 43.3 µm (60 min) | ||||
| 65 µm (120 min) (ED, 3 mg/ear) | PB 48.3 µm (120 min) | ||||
| 93.24 (15 min) (%Inhibition) | PB 97.3 (15 min) (%Inhibition) | [ | |||
| 89 (30 min) (%Inhibition) | PB 85 (30 min) (%Inhibition) | ||||
| 73 (60 min) (%Inhibition) | PB 74 (60 min) (%Inhibition) | ||||
| 54.65 (120 min) (%Inhibition) | PB 66.28 (120 min) (%Inhibition) | ||||
| Carrageenan-induced hind paw edema/Male Sprague Dawley rats | 0.12 mL (1 h) (EV, 600 mg/kg) | DC 0.16 (1 h) (EV) | [ | ||
| 0.20 mL (3 h) (EV, 600 mg/kg) | DC 0.21 (3 h) (EV) | ||||
| 66.2 (1 h) (%Inhibition, 600 mg/kg) | DC 55.09 (1 h) (%Inhibition) | [ | |||
| 56.74 (3 h) (%Inhibition, 600 mg/kg) | DC 54.61 (3 h) (%Inhibition) | ||||
| Leaves/EtOH extract | Anti-inflammatory | Carrageenan-induced hind paw edema/Male Sprague Dawley rats | 5.75 (180 min) (%Oedema, 300 mg/kg) | Indo 3.46 (180 min) (%Oedema) | [ |
| 87.9 (%Inhibition, 300 mg/kg) | 92.7 Indo (180 min) (%Inhibition) | [ | |||
| Analgesic | Acetic acid-induced writhing/Adult Balb/calbino mice | 20.3 (15 min) (Mean of writhings) | 19.0 (15 min) (Mean of writhings) | [ | |
| 60.7 (15 min) (%Inhibition) | 63.2 (15 min) (%Inhibition) | [ | |||
| Cytotoxicity | EA.hy926 cells/MTT assay | 54.9 (%Cell viability, 100 µg/mL) | - | [ | |
| 27.5 (%Cell viability, 200 µg/mL) | - | [ | |||
| 26.4 (%Cell viability, 400 µg/mL) | - | [ | |||
| Lipase inhibitory | 3T3-L1 adipocytes/Pancreatic lipase assay | 1708.35 µg/mL (IC50, 250–1000 µg/mL) | Orlistat 68.23 µg/mL (IC50) | [ | |
| Antihyperlipidemic | 3T3-L1 adipocytes/Lipid accumulation | 76.87 (%Inhibition, 750 µg/mL) | - | [ | |
| 71.93 (%Inhibition, 1000 µg/mL) | - | [ | |||
| Leaves/H2O extract | Anti-dyslipidemia | Prediabetic patients/Clinical trials | 109.22 mg/dL (TG, 1.5 g/once/12 weeks) | Placebo 145.56 mg/dL (TG) | [ |
| 122.20 mg/dL (LDL-C, 1.5 g/once/12 weeks) | Placebo 142.07 mg/dL (LDL-C) | [ | |||
| 57.56 mg/dL (HDL-C, 1.5 g/once/12 weeks) | Placebo 46.44 mg/dL (HDL-C) | [ | |||
| Fibroblast hyperproliferation inhibition | Flowcytometry analysis/ | 1.3 (%Fibroblast density, 20 µmol/L) | Control 1.5 (%Fibroblast density) | [ | |
| 1.0 (%Fibroblast density, 40 µmol/L) | - | [ | |||
| 0.7 (%Fibroblast density, 80 µmol/L) | - | [ | |||
| Leaves/MeOH extract | Antidiabetic | Normoglycemic/Wistar albino rats | 72.67 mg/dL (24 h) (Plasma glucose, 200 mg/kg) | Glibenclamide 73.67 mg/dL (24 h) (Plasma glucose) | [ |
| 71.67 mg/dL (24 h) (Plasma glucose, 400 mg/kg) | [ | ||||
| STZ-induced hyperglycemia/Wistar albino rats | 190.0 mg/dL (24 h) (Plasma glucose, 200 mg/kg) | Glibenclamide 168.0 mg/dL (24 h) (Plasma glucose) | [ | ||
| 172.83 mg/dL (24 h) (Plasma glucose, 400 mg/kg) | - | [ | |||
| Milk production | Total milk yield/lactating rats | 6.82 g/L/day (23 h) (Milk yield, 750 mg/kg) | Domperidone 7.17 g/L/day | [ | |
| Growth hormone promotion | 1963.25 pg/µL (Serum growth hormone level, 750 mg/kg) | Domperidone 409.46 pg/µL (Serum growth hormone level) | [ | ||
| Weight gain | Bodyweight gain/Wistar rat dams | 8.44 (%Dams body weight gain) | Domperidone 0.66 (%Dams body weight gain) | [ | |
| Leaves/Et OH extract | Antioxidant | DPPH scavenging/DPPH assay | 96.4 µmol TE/g fw (%DPPH scavenging, 100 mg/mL) | - | [ |
| 24.45 µg/mL (IC50, DPPH scavenging) | [ | ||||
| DPPH scavenging/DPPH assay | 42.24 µg/mL (IC50, DPPH scavenging) | α-Tocopherol 35.57 µg/mL (IC50, DPPH scavenging) | [ | ||
| ABTS scavenging/TEAC method | 3.75 µmol TE/g fw, ABTS scavenging | - | [ | ||
| Ferric-reducing power/FRAP assay | 81.1 (µmol TE/g fw, Ferric-reducing | - | [ | ||
| Inhibition of lipid oxidation/TBA method | 98.5 (%Inhibition) | - | [ | ||
| β-Carotene-linoleic scavenging activity/β-carotene bleaching method | 59.8 (%Antioxidant activity) | BHA 93.5 (% Antioxidant activity) | [ | ||
Control*: inflamed control; Phenylbutazone: PB; Diclofenac: DC; Indomethacin: Indo; ED: edema thickness; EV: edema volume; AA: antioxidant activity.
Figure 2Structures of compounds 10–25.
Figure 3Structures of compounds 26–33.
Figure 4Structures of compounds 34–39.
Figure 5Structures of compounds 40–43.
Biological activity of reported metabolites from Pluchea indica.
| Compound Name | Biological Activity | Assay, Organism, or Cell Line | Biological Results | Ref. | |
|---|---|---|---|---|---|
| Compound | Positive Control | ||||
| Caryolane-1,9β-diol ( | Anti-inflammatory/inhibition of NO production | LPS-stimulated production in RAW 264.7 macrophages cells | 104.8 (NRC % inhibition) | Dexamethasone 62.2 (NRC % inhibition) | [ |
| (8R,9R)-Isocaryolane-8,9-diol ( | Anti-inflammatory/inhibition of NO production | LPS-stimulated production in RAW 264.7 macrophages cells | 95.1 (NRC % inhibition) | Dexamethasone 62.2 (NRC % inhibition) | [ |
| Clovane-2α,9β-diol ( | Anti-inflammatory/inhibition of NO production | LPS-stimulated production in RAW 264.7 macrophages cells | 101.6 (NRC % inhibition) | Dexamethasone 62.2 (NRC % inhibition) | [ |
| Valenc-1(10)-ene-8,11-diol ( | Anti-inflammatory/inhibition of NO production | LPS-stimulated production in RAW 264.7 macrophages cells | 103.8 (NRC % inhibition) | Dexamethasone 62.2 (NRC % inhibition) | [ |
| Stigmasterol ( | Anti-inflammatory/inhibition of NO production | LPS-stimulated production in RAW 264.7 macrophages cells | 92.5 (NRC % inhibition) | Dexamethasone 62.2 (NRC % inhibition) | [ |
| 3,5-Di-O-caffeoylquinic acid ( | α-Glucosidase inhibition | Colorimetric/Rat intestinal maltase | 1166 µM (IC50) | Acarbose 0.5 µM (IC50) | [ |
| 4,5-Di-O-caffeoylquinic acid methyl ester ( | α-Glucosidase inhibition | Colorimetric/Rat intestinal maltase | 208.0 µM (IC50) | Acarbose 0.5 µM (IC50) | [ |
| 3,4,5-Tri-O-caffeoylquinic acid ( | α-Glucosidase inhibition | Colorimetric/Rat intestinal maltase | 13.0 µM (IC50) | Acarbose 0.5 µM (IC50) | [ |
| Collagenase inhibition | Fluorometric/Collagenase type IV | 1.5 µM (IC50) | Phosphramidon 7.4 µM (IC50) | [ | |
| MMP-2 inhibition | Fluorometric/MMP-2 proenzyme | 2.5 µM (IC50) | Chlorhexidine 7.3 µM (IC50) | [ | |
| MMP-9 inhibition | Fluorometric/MMP-9 monomer | 6.4 µM (IC50) | Chlorhexidine 25.2 µM (IC50) | [ | |
| 3,4,5-tri-O-caffeoylquinic acid methyl ester ( | α-Glucosidase inhibition | Colorimetric/Rat intestinal maltase | 2.0 µM (IC50) | Acarbose 0.5 µM (IC50) | [ |
| 1,3,4,5-Tetra-O-Caffeoylquinic acid ( | α-Glucosidase inhibition | Colorimetric/Rat intestinal maltase | 11.0 µM (IC50) | Acarbose 0.5 µM (IC50) | [ |
| Collagenase inhibition | Fluorometric/Collagenase type IV | 6.3 µM (IC50) | Phosphramidon 7.4 µM (IC50) | [ | |
| MMP-2 inhibition | Fluorometric/MMP-2 proenzyme | 18.4 µM (IC50) | Chlorhexidine 7.3 µM (IC50) | [ | |
| MMP-9 inhibition | Fluorometric/MMP-9 monomer | 16.8 µM (IC50) | Chlorhexidine 25.2 µM (IC50) | [ | |
| Quercetin ( | Collagenase inhibition | Fluorometric/Collagenase type IV | 16.9 µM (IC50) | Phosphramidon 7.4 µM (IC50) | [ |
| CYP2A6 inhibition | Enzymatic reconstitution | 2.66 µM (IC50) | Methoxsalen 0.19 µM (IC50) | [ | |
| CYP2A13 inhibition | 0.80 µM (IC50) | Methoxsalen 0.43 µM (IC50) | [ | ||
| Apigenin ( | CYP2A6 inhibition | Enzymatic reconstitution | 0.9 µM (IC50) | Methoxsalen 0.19 µM (IC50) | [ |
| CYP2A13 inhibition | 0.05 µM (IC50) | Methoxsalen 0.43 µM (IC50) | [ | ||
| Luteolin ( | CYP2A6 inhibition | Enzymatic reconstitution | 1.38 µM (IC50) | Methoxsalen 0.19 µM (IC50) | [ |
| CYP2A13 inhibition | 0.18 µM (IC50) | Methoxsalen 0.43 µM (IC50) | [ | ||
| Chrysoeriol ( | CYP2A6 inhibition | Enzymatic reconstitution | 1.14 µM (IC50) | Methoxsalen 0.19 µM (IC50) | [ |
| CYP2A13 inhibition | 0.82 µM (IC50) | Methoxsalen 0.43 µM (IC50) | [ | ||
| 3,4-Dihydroxy benzaldehyde ( | Anti-inflammatory/inhibition of NO production | LPS-stimulated production in RAW 264.7 macrophages cells | 92.9 (NRC % inhibition) | Dexamethasone 62.2 (NRC % inhibition) | [ |
| Vanillin ( | Anti-inflammatory/inhibition of NO production | LPS-stimulated production in RAW 264.7 macrophages cells | 99.6 (NRC % inhibition) | Dexamethasone 62.2 (NRC % inhibition) | [ |
| 3,4-Dihydroxy-5-methoxybenzaldehyde ( | Anti-inflammatory/inhibition of NO production | LPS-stimulated production in RAW 264.7 macrophages cells | 103.9 (NRC % inhibition) | Dexamethasone 62.2 (NRC % inhibition) | [ |
| Syringicaldehyde ( | Anti-inflammatory/inhibition of NO production | LPS-stimulated production in RAW 264.7 macrophages cells | 92.6 (NRC % inhibition) | Dexamethasone 62.2 (NRC % inhibition) | [ |
| Trans-Coniferyl aldehyde ( | Anti-inflammatory/inhibition of NO production | LPS-stimulated production in RAW 264.7 macrophages cells | 94.2 (NRC % inhibition) | Dexamethasone 62.2 (NRC % inhibition) | [ |
| Dibutylphthalate ( | Anti-inflammatory/inhibition of NO production | LPS-stimulated production in RAW 264.7 macrophages cells | 101.1 (NRC % inhibition) | Dexamethasone 62.2 (NRC % inhibition) | [ |
| Ethyl caffeate ( | Anti-inflammatory/inhibition of NO production | LPS-stimulated production in RAW 264.7 macrophages cells | 77.9 (NRC % inhibition) | Dexamethasone 62.2 (NRC % inhibition) | [ |
| 2,3-Dihydroxy-1-(4-hydroxy-3-methoxyphenyl)-propan-1-one ( | Anti-inflammatory/inhibition of NO production | LPS-stimulated production in RAW 264.7 macrophages cells | 100.9 (NRC % inhibition) | Dexamethasone 62.2 (NRC % inhibition) | [ |
| Esculetin ( | Anti-inflammatory/inhibition of NO production | LPS-stimulated production in RAW 264.7 macrophages cells | 88.5 (NRC % inhibition) | Dexamethasone 62.2 (NRC % inhibition) | [ |
| (+)-Diasyringaresinol ( | Anti-inflammatory/inhibition of NO production | LPS-stimulated production in RAW 264.7 macrophages cells | 101.7 (NRC % inhibition) | Dexamethasone 62.2 (NRC % inhibition) | [ |
| Threo-2,3-Bis(4-hydroxy-3-methoxyphenyl)-3-ethoxypropan-1-ol ( | Anti-inflammatory/inhibition of NO production | LPS-stimulated production in RAW 264.7 macrophages cells | 101.7 (NRC % inhibition) | Dexamethasone 62.2 (NRC % inhibition) | [ |
| Erythro-2,3-Bis(4-hydroxy-3-methoxyphenyl)-3-ethoxypropan-1-ol ( | Anti-inflammatory/inhibition of NO production | LPS-stimulated production in RAW 264.7 macrophages cells | 99.7 (NRC % inhibition) | Dexamethasone 62.2 (NRC % inhibition) | [ |
| (+)-Isolariciresinol ( | Anti-inflammatory/inhibition of NO production | LPS-stimulated production in RAW 264.7 macrophages cells | 101.9 (NRC % inhibition) | Dexamethasone 62.2 (NRC % inhibition) | [ |
| (+)-9′-Isovaleryllariciresinol ( | Anti-inflammatory/inhibition of NO production | LPS-stimulated production in RAW 264.7 macrophages cells | 77.6 (NRC % inhibition) | Dexamethasone 62.2 (NRC % inhibition) | [ |
| 2-(Prop-1-inyl)-5-(5,6-dihydroxyhexa-1,3-diinyl) thiophene ( | CYP2A6 inhibition | Enzymatic reconstitution | 3.90 µM (IC50) | Methoxsalen 0.19 µM (IC50) | [ |
| CYP2A13 inhibition | 2.40 µM (IC50) | Methoxsalen 0.43 µM (IC50) | [ | ||
| Anti-amoebic | Cell count/ | 50 µg/mL (MIC) | Metronidazole 5 µg/mL (MIC) | [ | |
| 2-(Prop-1-inyl)-5-(6-acetoxy-5-hydroxyhexa-1, 3-diinyl) thiophene ( | CYP2A6 inhibition | Enzymatic reconstitution | 4.44 µM (IC50) | Methoxsalen 0.19 µM (IC50) | [ |
| CYP2A13 inhibition | 2.94 µM (IC50) | Methoxsalen 0.43 µM (IC50) | [ | ||
| 2-(Penta-1,3-diyn-1-yl)-5-(4-acetoxy-3-hydroxybuta-1-yn-1-yl) thiophene ( | CYP2A6 inhibition | Enzymatic reconstitution | 6.43 µM (IC50) | Methoxsalen 0.19 µM (IC50) | [ |
| CYP2A13 inhibition | 6.18 µM (IC50) | Methoxsalen 0.43 µM (IC50) | [ | ||
| 3″R-Pluthiophenol ( | Anti-inflammatory/inhibition of NO production | LPS-stimulated production in RAW 264.7 macrophages cells | 84.5 (NRC % inhibition) | Dexamethasone 62.2 (NRC % inhibition) | [ |
| 3″R-Pluthiophenol-4″-acetate ( | Anti-inflammatory/inhibition of NO production | LPS-stimulated production in RAW 264.7 macrophages cells | 83.4 (NRC % inhibition) | Dexamethasone 62.2 (NRC % inhibition) | [ |
| 3″-Ethoxy-3″S-pluthiophenol ( | Anti-inflammatory/inhibition of NO production | LPS-stimulated production in RAW 264.7 macrophages cells | 86.9 (NRC % inhibition) | Dexamethasone 62.2 (NRC % inhibition) | [ |
| 3″-Ethoxy-3″S-pluthiophenol-4″-acetate ( | Anti-inflammatory/inhibition of NO production | LPS-stimulated production in RAW 264.7 macrophages cells | 90.1 (NRC % inhibition) | Dexamethasone 62.2 (NRC % inhibition) | [ |
| 9,12,13-Trihydroxyoctadeca-10(E),15(Z)-dienoic acid ( | Anti-inflammatory/inhibition of NO production | LPS-stimulated production in RAW 264.7 macrophages cells | 90.3 (NRC % inhibition) | Dexamethasone 62.2 (NRC % inhibition) | [ |
| Pinellic acid ( | Anti-inflammatory/inhibition of NO production | LPS-stimulated production in RAW 264.7 macrophages cells | 89.5 (NRC % inhibition) | Dexamethasone 62.2 (NRC % inhibition) | [ |
| Methyl 9-hydroxynonanoate ( | Anti-inflammatory/inhibition of NO production | LPS-stimulated production in RAW 264.7 macrophages cells | 93.6 (NRC % inhibition) | Dexamethasone 62.2 (NRC % inhibition) | [ |
| Triethyl citrate ( | Anti-inflammatory/inhibition of NO production | LPS-stimulated production in RAW 264.7 macrophages cells | 91.1 (NRC % inhibition) | Dexamethasone 62.2 (NRC % inhibition) | [ |
| Fraxinellone ( | Anti-inflammatory/inhibition of NO production | LPS-stimulated production in RAW 264.7 macrophages cells | 52.1 (NRC % inhibition) | Dexamethasone 62.2 (NRC % inhibition) | [ |
| Adenosine ( | Anti-inflammatory/inhibition of NO production | LPS-stimulated production in RAW 264.7 macrophages cells | 88.7 (NRC % inhibition) | Dexamethasone 62.2 (NRC % inhibition) | [ |
Figure 6Structures of compounds 44–57.
Figure 7Structures of compounds 58–69.
Figure 8Structures of compounds 70–83.
Figure 9Structures of compounds 84–91.
Figure 10Structures of compounds 92–96.
Figure 11Structures of compounds 97–101.
Figure 12Structures of compounds 102–112.
Figure 13Structures of compounds 113–122.
Figure 14Number of metabolites from various classes reported from P. indica. MT: Monoterpenes; ST: Sesquiterpenes; TT: Triterpenes; CQs: Caffeoylquinic acid derivatives; Flav: Flavonoids; Phen: Phenolics; Lig: Lignans; Thioph: Thiophenes.
Figure 15Number of reported metabolites from P. indica from various countries.
Figure 16Number of metabolites isolated from different parts of P. indica.